Addex Therapeutics Financials

ADXN Stock

USD 7.90 0.20 2.60%

Based on the key indicators related to Addex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Addex Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in March. At this time, Addex Therapeutics' Other Assets are very stable compared to the past year. As of the 7th of February 2026, Short Term Investments is likely to grow to about 13.8 K, while Total Assets are likely to drop about 9.1 M.

Yuan Drop

Covid

Interest Hikes

Addex Therapeutics Balance Sheet Chart

At this time, Addex Therapeutics' Other Assets are very stable compared to the past year. As of the 7th of February 2026, Short Term Investments is likely to grow to about 13.8 K, while Total Assets are likely to drop about 9.1 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Key indicators impacting Addex Therapeutics' financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Debt Equity Ratio

0.0037

0.0039

Notably Down

Pretty Stable

Current Ratio

6.33

5.07

Fairly Up

Very volatile

Investors should never underestimate Addex Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Addex Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Addex Therapeutics.

Net Income

8.52 Million

Build AI portfolio with Addex Stock

Understanding current and past Addex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Addex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Addex Therapeutics' assets may result in an increase in income on the income statement.

Addex Therapeutics Stock Summary

Addex Therapeutics competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Addex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.

Foreign Associate	Switzerland
Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US00654J2069
Business Address	Chemin des Mines,
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	www.addextherapeutics.com
Phone	41 22 884 1555
Currency	USD - US Dollar

Addex Therapeutics Key Financial Ratios

	Return On Equity	-0.73
	Operating Margin	(14.04) %
	Price To Sales	59.84 X
	Revenue	404.1 K
	Gross Profit	(525.65 K)

More Fundamentals

Addex Therapeutics Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	22.5M	8.3M	4.6M	10.7M	9.6M	9.1M
Other Current Liab	1.9M	1.6M	1.2M	518.8K	467.0K	443.6K
Net Debt	(20.0M)	(6.6M)	(3.5M)	(3.3M)	(3.8M)	(4.0M)
Retained Earnings	(329.1M)	(349.9M)	(360.4M)	(353.4M)	(318.0M)	(333.9M)
Accounts Payable	1.8M	1.3M	984.4K	253.3K	228.0K	216.6K
Cash	20.5M	7.0M	3.9M	3.3M	3.0M	2.9M
Other Current Assets	1.1M	270.4K	217.0K	177.6K	159.9K	151.9K
Total Liab	5.6M	3.4M	3.5M	1.0M	900.9K	855.9K
Total Current Assets	21.9M	7.8M	4.2M	3.5M	3.2M	3.0M
Short Term Debt	287.7K	286.1K	274.0K	7.3K	8.4K	8.0K
Net Receivables	324.4K	598.3K	151.3K	15.5K	14.0K	13.3K
Net Tangible Assets	25.5M	14.6M	16.9M	4.9M	5.6M	5.4M
Other Assets	68.9K	59.1K	57.9K	54.4K	48.9K	66.0K
Net Invested Capital	16.9M	4.9M	1.1M	9.7M	8.7M	11.3M
Net Working Capital	17.8M	4.5M	1.3M	2.7M	2.5M	2.3M

Addex Therapeutics Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	63.0K	48.9K	21.6K	3.5K	3.2K	3.0K
Total Revenue	2.9M	1.4M	1.6M	404.1K	363.7K	345.5K
Gross Profit	2.9M	1.4M	1.6M	404.1K	464.7K	488.0K
Operating Income	(15.5M)	(10.5M)	(2.2M)	(2.8M)	(3.2M)	(3.3M)
Ebit	(15.3M)	(10.8M)	(2.5M)	(4.9M)	(5.6M)	(5.9M)
Research Development	9.0M	7.9M	942.7K	435.2K	391.7K	372.1K
Ebitda	(14.9M)	(10.5M)	(2.2M)	(4.6M)	(5.3M)	(5.6M)
Income Before Tax	(15.4M)	(10.8M)	(2.5M)	(4.9M)	(5.6M)	(5.9M)
Net Income	(15.4M)	(20.8M)	(10.6M)	7.1M	8.1M	8.5M
Income Tax Expense	207.8K	116.4K	123.9K	21.6K	19.4K	18.5K
Cost Of Revenue	12.8M	14.6M	6.9M	854.3K	768.9K	730.4K
Interest Income	5.3K	29.3K	64.0K	9.2K	8.2K	7.8K
Net Interest Income	(57.7K)	(19.6K)	42.4K	5.6K	6.5K	6.8K

Addex Therapeutics Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Change In Cash	1.8M	(13.5M)	(3.1M)	(523.7K)	(471.4K)	(494.9K)
Free Cash Flow	(14.7M)	(16.4M)	(8.0M)	(5.4M)	(6.2M)	(6.5M)
Depreciation	347.6K	323.1K	306.0K	260.1K	234.1K	222.4K
Other Non Cash Items	32.9K	204.1K	249.6K	(11.5M)	(10.3M)	(9.8M)
Capital Expenditures	31.5K	581.0	6.8K	1.3K	1.1K	1.1K
Net Income	(15.4M)	(20.8M)	(10.6M)	7.1M	8.1M	8.5M
End Period Cash Flow	20.5M	7.0M	3.9M	3.3M	3.0M	2.9M
Change To Inventory	1.5M	(883.8K)	427.4K	613.2K	705.2K	740.4K
Investments	1.2K	3.0K	(6.8K)	4.6M	5.3M	5.6M
Net Borrowings	(309.6K)	(288.1K)	(281.8K)	(73.7K)	(66.3K)	(69.6K)
Change To Netincome	2.3M	2.1M	1.1M	3.9M	4.5M	4.7M

Addex Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Addex Therapeutics's current stock value. Our valuation model uses many indicators to compare Addex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Addex Therapeutics competition to find correlations between indicators driving Addex Therapeutics's intrinsic value. More Info.

Addex Therapeutics is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Addex Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Addex Therapeutics' earnings, one of the primary drivers of an investment's value.

Most accounts from Addex Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.At this time, Addex Therapeutics' Other Assets are very stable compared to the past year. As of the 7th of February 2026, Short Term Investments is likely to grow to about 13.8 K, while Total Assets are likely to drop about 9.1 M.

	2023	2024	2025	2026 (projected)
Short and Long Term Debt Total	344.3K	42.0K	37.8K	35.9K
Total Assets	4.6M	10.7M	9.6M	9.1M

Short Long Term Debt Total Total Assets

Addex Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Non Current Liabilities Total	Net Receivables
Total Assets		0.05	0.21	0.71	0.99	0.72	0.1	-0.99	0.57	0.62	0.98	0.16	0.1	0.98	-0.12	-0.18	0.77	-0.48	0.69	0.33	0.99	0.16	-0.2	0.33	0.42	0.48
Short Long Term Debt Total	0.05		0.28	0.37	-0.03	0.0	0.05	-0.15	0.03	0.23	0.16	-0.72	0.36	0.16	-0.44	-0.93	0.09	-0.17	0.42	-0.05	0.17	0.15	-0.32	0.51	0.44	0.21
Other Current Liab	0.21	0.28		0.33	0.17	0.26	0.01	-0.21	0.24	-0.16	0.22	-0.17	0.44	0.22	-0.21	-0.33	0.22	-0.31	0.34	0.31	0.24	0.33	-0.29	0.24	0.29	0.52
Total Current Liabilities	0.71	0.37	0.33		0.61	0.78	0.09	-0.69	0.33	0.86	0.7	0.01	0.37	0.7	-0.23	-0.44	0.89	-0.31	0.98	0.6	0.72	0.37	-0.33	0.28	0.61	0.62
Total Stockholder Equity	0.99	-0.03	0.17	0.61		0.68	0.07	-0.98	0.59	0.55	0.97	0.18	0.06	0.97	-0.11	-0.12	0.71	-0.49	0.59	0.27	0.97	0.09	-0.18	0.29	0.33	0.44
Property Plant And Equipment Net	0.72	0.0	0.26	0.78	0.68		-0.23	-0.65	0.74	0.74	0.65	0.35	0.42	0.65	-0.5	-0.25	0.9	-0.64	0.68	0.56	0.67	-0.02	-0.56	-0.13	0.15	0.78
Current Deferred Revenue	0.1	0.05	0.01	0.09	0.07	-0.23		-0.15	-0.24	-0.09	0.16	-0.24	-0.52	0.16	0.5	0.12	-0.07	0.16	0.21	-0.22	0.15	0.59	0.62	0.45	0.59	-0.45
Net Debt	-0.99	-0.15	-0.21	-0.69	-0.98	-0.65	-0.15		-0.56	-0.58	-1.0	0.0	-0.04	-1.0	0.12	0.26	-0.72	0.5	-0.68	-0.31	-1.0	-0.22	0.17	-0.41	-0.45	-0.44
Retained Earnings	0.57	0.03	0.24	0.33	0.59	0.74	-0.24	-0.56		0.3	0.55	0.12	0.32	0.55	-0.73	-0.35	0.52	-0.91	0.24	0.13	0.55	-0.23	-0.65	-0.11	-0.15	0.65
Accounts Payable	0.62	0.23	-0.16	0.86	0.55	0.74	-0.09	-0.58	0.3		0.58	0.17	0.28	0.58	-0.26	-0.32	0.85	-0.22	0.8	0.49	0.6	0.06	-0.31	0.07	0.35	0.51
Cash	0.98	0.16	0.22	0.7	0.97	0.65	0.16	-1.0	0.55	0.58		-0.02	0.04	1.0	-0.12	-0.27	0.72	-0.5	0.69	0.32	1.0	0.24	-0.17	0.42	0.46	0.44
Non Current Assets Total	0.16	-0.72	-0.17	0.01	0.18	0.35	-0.24	0.0	0.12	0.17	-0.02		0.24	-0.02	0.09	0.59	0.25	0.07	-0.05	-0.04	-0.01	-0.47	-0.1	-0.5	-0.24	0.13
Non Currrent Assets Other	0.1	0.36	0.44	0.37	0.06	0.42	-0.52	-0.04	0.32	0.28	0.04	0.24		0.04	-0.62	-0.48	0.3	-0.27	0.31	0.06	0.06	-0.37	-0.77	-0.18	0.0	0.62
Cash And Short Term Investments	0.98	0.16	0.22	0.7	0.97	0.65	0.16	-1.0	0.55	0.58	1.0	-0.02	0.04		-0.12	-0.27	0.72	-0.5	0.69	0.32	1.0	0.24	-0.17	0.42	0.46	0.44
Common Stock Total Equity	-0.12	-0.44	-0.21	-0.23	-0.11	-0.5	0.5	0.12	-0.73	-0.26	-0.12	0.09	-0.62	-0.12		0.71	-0.27	0.71	-0.13	0.01	-0.13	0.45	0.85	0.21	0.27	-0.64
Common Stock Shares Outstanding	-0.18	-0.93	-0.33	-0.44	-0.12	-0.25	0.12	0.26	-0.35	-0.32	-0.27	0.59	-0.48	-0.27	0.71		-0.25	0.45	-0.43	-0.01	-0.28	-0.01	0.56	-0.37	-0.27	-0.46
Other Current Assets	0.77	0.09	0.22	0.89	0.71	0.9	-0.07	-0.72	0.52	0.85	0.72	0.25	0.3	0.72	-0.27	-0.25		-0.48	0.85	0.62	0.74	0.19	-0.36	0.22	0.44	0.65
Other Stockholder Equity	-0.48	-0.17	-0.31	-0.31	-0.49	-0.64	0.16	0.5	-0.91	-0.22	-0.5	0.07	-0.27	-0.5	0.71	0.45	-0.48		-0.25	-0.17	-0.5	0.08	0.61	-0.07	0.04	-0.59
Total Liab	0.69	0.42	0.34	0.98	0.59	0.68	0.21	-0.68	0.24	0.8	0.69	-0.05	0.31	0.69	-0.13	-0.43	0.85	-0.25		0.54	0.71	0.46	-0.24	0.42	0.75	0.51
Property Plant And Equipment Gross	0.33	-0.05	0.31	0.6	0.27	0.56	-0.22	-0.31	0.13	0.49	0.32	-0.04	0.06	0.32	0.01	-0.01	0.62	-0.17	0.54		0.34	0.49	-0.1	-0.01	0.15	0.51
Total Current Assets	0.99	0.17	0.24	0.72	0.97	0.67	0.15	-1.0	0.55	0.6	1.0	-0.01	0.06	1.0	-0.13	-0.28	0.74	-0.5	0.71	0.34		0.24	-0.18	0.42	0.47	0.46
Short Term Debt	0.16	0.15	0.33	0.37	0.09	-0.02	0.59	-0.22	-0.23	0.06	0.24	-0.47	-0.37	0.24	0.45	-0.01	0.19	0.08	0.46	0.49	0.24		0.33	0.5	0.63	-0.13
Intangible Assets	-0.2	-0.32	-0.29	-0.33	-0.18	-0.56	0.62	0.17	-0.65	-0.31	-0.17	-0.1	-0.77	-0.17	0.85	0.56	-0.36	0.61	-0.24	-0.1	-0.18	0.33		0.22	0.16	-0.66
Common Stock	0.33	0.51	0.24	0.28	0.29	-0.13	0.45	-0.41	-0.11	0.07	0.42	-0.5	-0.18	0.42	0.21	-0.37	0.22	-0.07	0.42	-0.01	0.42	0.5	0.22		0.78	-0.17
Non Current Liabilities Total	0.42	0.44	0.29	0.61	0.33	0.15	0.59	-0.45	-0.15	0.35	0.46	-0.24	0.0	0.46	0.27	-0.27	0.44	0.04	0.75	0.15	0.47	0.63	0.16	0.78		-0.04
Net Receivables	0.48	0.21	0.52	0.62	0.44	0.78	-0.45	-0.44	0.65	0.51	0.44	0.13	0.62	0.44	-0.64	-0.46	0.65	-0.59	0.51	0.51	0.46	-0.13	-0.66	-0.17	-0.04

Click cells to compare fundamentals

Addex Therapeutics Account Relationship Matchups

Addex Therapeutics balance sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	22.5M	8.3M	4.6M	10.7M	9.6M	9.1M
Other Current Liab	1.9M	1.6M	1.2M	518.8K	467.0K	443.6K
Net Debt	(20.0M)	(6.6M)	(3.5M)	(3.3M)	(3.8M)	(4.0M)
Retained Earnings	(329.1M)	(349.9M)	(360.4M)	(353.4M)	(318.0M)	(333.9M)
Accounts Payable	1.8M	1.3M	984.4K	253.3K	228.0K	216.6K
Cash	20.5M	7.0M	3.9M	3.3M	3.0M	2.9M
Other Current Assets	1.1M	270.4K	217.0K	177.6K	159.9K	151.9K
Total Liab	5.6M	3.4M	3.5M	1.0M	900.9K	855.9K
Total Current Assets	21.9M	7.8M	4.2M	3.5M	3.2M	3.0M
Short Term Debt	287.7K	286.1K	274.0K	7.3K	8.4K	8.0K
Net Receivables	324.4K	598.3K	151.3K	15.5K	14.0K	13.3K
Net Tangible Assets	25.5M	14.6M	16.9M	4.9M	5.6M	5.4M
Other Assets	68.9K	59.1K	57.9K	54.4K	48.9K	66.0K
Net Invested Capital	16.9M	4.9M	1.1M	9.7M	8.7M	11.3M
Net Working Capital	17.8M	4.5M	1.3M	2.7M	2.5M	2.3M

Today, most investors in Addex Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Addex Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Addex Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.004493)

At this time, Addex Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year.

Addex Therapeutics February 7, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Addex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Addex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Addex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Addex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Addex Therapeutics's daily price indicators and compare them against related drivers.

	Information Ratio	(0.04)
	Maximum Drawdown	25.13
	Value At Risk	(7.12)
	Potential Upside	7.85

When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:

How To Invest In Addex

Details

Is Addex Stock a good investment?

Details

What is Addex Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median.

To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Will Biotechnology sector continue expanding? Could Addex diversify its offerings? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Addex Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(9.28)

Revenue Per Share

0.24

Quarterly Revenue Growth

(0.15)

Return On Assets

(0.16)

Return On Equity

(0.73)

The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Understanding that Addex Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Addex Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Addex Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Addex Therapeutics Financials

Addex Therapeutics Balance Sheet Chart

Net Income

8.52 Million

Addex Therapeutics Stock Summary

Addex Therapeutics Key Financial Ratios

Addex Therapeutics Key Balance Sheet Accounts

Addex Therapeutics Key Income Statement Accounts

Addex Therapeutics Key Cash Accounts

Addex Financial Ratios Relationships

Addex Therapeutics balance sheet Correlations

Addex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Addex Therapeutics balance sheet Accounts

Price Earnings To Growth Ratio

(0.004493)

Addex Therapeutics February 7, 2026 Opportunity Range

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Cash	+ 0.98	Total Assets

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Assets
Net Debt	- 0.98	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.93	Short Long Term Debt Total